Cochrane Abstracts
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral Versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434253/all/Oral_versus_intravenous_steroids_for_treatment_of_relapses_in_multiple_sclerosis.
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434253/all/Oral_versus_intravenous_steroids_for_treatment_of_relapses_in_multiple_sclerosis. Accessed January 17, 2025.
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434253/all/Oral_versus_intravenous_steroids_for_treatment_of_relapses_in_multiple_sclerosis
Oral Versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434253/all/Oral_versus_intravenous_steroids_for_treatment_of_relapses_in_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
ID - 434253
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434253/all/Oral_versus_intravenous_steroids_for_treatment_of_relapses_in_multiple_sclerosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
